patellamide C: from ascidian Lissoclinum patella; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9767970 |
| CHEMBL ID | 501924 |
| CHEBI ID | 80064 |
| SCHEMBL ID | 17251953 |
| MeSH ID | M0432790 |
| Synonym |
|---|
| patellamide c |
| chebi:80064 , |
| CHEMBL501924 |
| SCHEMBL17251953 |
| (4s,7r,8s,11r,18s,21r,22s,25r)-11-benzyl-4-[(2s)-butan-2-yl]-7,21,25-trimethyl-18-propan-2-yl-6,20-dioxa-13,27-dithia-3,10,17,24,29,30,31,32-octazapentacyclo[24.2.1.15,8.112,15.119,22]dotriaconta-1(28),5(32),12(31),14,19(30),26(29)-hexaene-2,9,16,23-tetro |
| Q27149216 |
| Class | Description |
|---|---|
| cyclic peptide | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID98555 | Concentration required to cause 50% inhibition against murine leukemia L1210 cell line; 2-4 ug/mL | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | New cyclic peptides with cytotoxic activity from the ascidian Lissoclinum patella. |
| AID355626 | Cytotoxicity against human KB cells | |||
| AID355640 | Cytotoxicity against human H116 cells at 200 ug/disk by corbett disk diffusion assay | |||
| AID403548 | Cytotoxicity against human multi drug-resistant CEM/VBL100 cells in presence of vinblastine | 1998 | Journal of natural products, Dec, Volume: 61, Issue:12 | New cyclic peptides from the ascidian Lissoclinum patella. |
| AID355629 | Cytotoxicity against mouse L1210 cells at 200 ug/disk by corbett disk diffusion assay | |||
| AID355635 | Cytotoxicity against mouse C38 cells at 200 ug/disk by corbett disk diffusion assay | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.59) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||